Good day, and thank you for standing by. Welcome to the InnovAge second quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You'll then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I want to hand the conference over to our first speaker today, Ryan Kubota, Director of Investor Relations. Please go ahead. Thank you, operator. Good afternoon, and thank you all for joining the InnovAge fiscal 2024 second quarter earnings call. With me today is Patrick Blair, President and CEO, and Ben Adams, CFO. Dr. Richard Feifer, Chief Medical Officer, will also be joining the Q&A portion of the call. Today, after the market closed, we issued a press release containing detailed information on our quarterly results for our fiscal second quarter, 2024. You may access the release on our investor relations sections of our company website, innovage.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, February 6, 2024, and have not been updated subsequent to this call. During our call, we refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our earnings press release posted on our website. We will also be making forward-looking statements, including statements related to our full fiscal year projections, future growth prospects, Florida de novo centers, our acquisition of Concerto Care, our payer capabilities and Clinical Value Initiatives, the status of current and future regulatory actions, and other expectations. Listeners are cautioned that all of our forward-looking statements involve certain assumptions and are inherently subject to risks and uncertainties that can cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in our Form 10-K Annual Report for fiscal year 2023 and our subsequent reports filed with the SEC, including our most recent quarterly report on Form 10-Q. After the completion of our prepared remarks, we will open the call for questions. I will now turn the call over to our President and CEO, Patrick Blair. Patrick? Thank you, Ryan, and good afternoon, everyone. I want to begin by expressing my continued appreciation to our colleagues, participants, government partners, and the investor community who support InnovAge. The company's second quarter results were consistent with our expectations and highlight the ongoing performance improvement across the business. It further demonstrates incremental progress in our broader transformation plan to accelerate responsible growth while restoring operating margin lost during the regulatory sanction period. We reported revenue of $189 million for the quarter, an increase of approximately 3.5% compared to the first quarter, and center- level contribution margin of $34 million, which represents a 17.8% margin. Adjusted EBITDA was $7.8 million for the quarter, which represents a significant improvement compared to the first quarter, which was approximately $2.2 million. Census increased to 6,780, which represents a quarter-over-quarter improvement of 3%. Now, a few highlights. Participant net enrollment growth for the quarter was solid at 195, which continues to strengthen our confidence in the value proposition we are delivering. Our clinical value initiatives, CVIs, as we refer to them, which focus on unnecessary utilization and lowering medical cost trends, are maturing in line with our expectations and beginning to translate into enhanced quality and greater operational efficiency, as evidenced by a quarter-over-quarter decrease in our participant expense, PMPM, of 0.7%. We are still in the early innings of this work, but we're pleased with the progress we're making. We are managing our non-center costs effectively in our enterprise service functions, resulting in a sequential decrease in general and administrative expenses as a percentage of revenue from 15.9%-13.4%. We completed the implementation of the new Epic EMR in all locations. On December 1st, we acquired Concerto Care PACE, which added two new centers in the highly strategic Southern California market. On January 1st, we officially opened our new center in Tampa and are now operational in six states: Colorado, California, Pennsylvania, New Mexico, Virginia, and Florida. With half our fiscal year behind us, we're pleased with our progress and remain laser focused on exiting fiscal 2024 with solid earnings momentum. While we have demonstrated strong sequential quarter-over-quarter progress, significant work remains to achieve our financial goals for the second half of fiscal 2024 and to create a glide path for successful fiscal 2025. As I mentioned last quarter, we have a great team, confidence in our plan, and it continues to come down to consistent execution. We remain focused on the levers that drive near-term performance while continuing to build a long-term foundation of compliance and operational excellence. Simply put, we believe we're on track to unlocking the full potential of the organization at an intentional pace, which will take perseverance and time. Before turning to our quarterly performance, I want to take a moment to address the California regulatory update included in our 10-Q. As you'll recall, we were released from enrollment sanctions in our Sacramento center by CMS in November of 2022. By the California Department of Health Care Services in May 2023. Underpinning that release was validation from both agencies that corrective actions had been resolved to their satisfaction and that there were no remaining systemic concerns. In October 2023, CMS and DHCS conducted the final annual routine audit of our Sacramento center, as required for all new PACE centers during their first three years of operations. Following that audit, CMS approved our corrective actions in accordance with their findings. DHCS notified us two weeks ago that it had identified deficiencies. Last week, they shared the specific findings with us. After careful review of the findings, which are similar to the CMS findings, which we are in the process of remediating, we are confident that we have in place the policies, processes, and systems to correct the identified issues. DHCS also communicated that it will be conducting a targeted medical review of our San Bernardino center. DHCS has suspended its state attestations in support of our planned de novo centers in Downey and Bakersfield, which were scheduled to open this summer, but as indicated, it will evaluate lifting the suspension upon resolution of the matter. We remain confident that we will successfully address any issues to the full satisfaction of DHCS, and upon satisfactory remediation, that DHCS will reinstate the attestations. We also remain confident with regard to our expansion plans. This is a highly regulated area, rightfully so. Audits and Corrective Actions are a normal course for all PACE organizations, given the populations we serve. We have seen the benefits of the foundational changes we've made in every center over the last two years to provide high-quality care. We work closely with our regulators on their audits and conduct our own audits in each center every month, and we've consistently seen a clear positive trend line. When opportunities for improvement at one center are identified, we make them quickly and then cascade learnings across the organization. I want to be clear, compliance has been my North Star since I joined the company two years ago, and that will always be the case. Our leaders share my commitment to transparency and embrace the opportunity to collaborate with state and federal regulators to continuously improve our business. I felt it was important to share this context and draw the critical distinction of where we are today relative to two and a half years ago. Now I'll turn to details about our recent performance, starting with existing center growth. New participant monthly enrollment continues above pre-sanction levels for the second consecutive quarter, consistent with our expectations. As I mentioned at the outset, we enrolled 195 participants in the quarter and have enrolled more 375 participants in the first half of the fiscal year. As we approach the third fiscal quarter, we anticipate some modest seasonality related to the Medicare Annual Enrollment period. This organic growth contributes to two key objectives: efficiently utilizing excess capacity in our centers, and new growth, especially in Colorado, helps rebalance the overall mix of our participant risk pool. We're pleased to see that our new participants reflect an appropriate balance of individuals living independently in the community and those that may require some level of supportive housing. We continue to see strong demand for our integrated solution that allows seniors to stay in their homes and communities and out of nursing homes. This demand is most evident in the sequential increase in total sales qualified leads, which is up approximately 11% from the prior quarter. Last quarter, we touched on enrollment as a joint effort between InnovAge and our state partners. While we are seeing aggregate enrollment consistent with our expectations, we continue to observe challenges in select markets which have resulted in enrollment processing delays, in part due to Medicaid Redetermination. The barriers we're experiencing include state enrollment resource constraints, post-public health emergency policy changes that now require in-person level of care assessments versus telephonic, and new state vendors who are still ramping up to targeted service levels. Recall that this does not affect the eligibility of potential participant, but rather the speed through which we can get them enrolled into PACE. However, lengthy delays can result in prospects evaluating other options and can translate into missed enrollment opportunities. Our state partners remain active and committed to resolving these issues with us as rapidly as possible. To state the positive, we're finding more eligible participants interested in joining InnovAge than we're currently enrolling today. On the de novo front, we're pleased to announce that we're operational at our New Tampa Center. Recall, this state-of-the-art center is approximately 42,000 sq ft and is expected to serve approximately 1,300 participants at maturity. Enrollment efforts are underway, and job number one is to begin expanding access to the many deserving eligible participants in the community. We believe Florida is an attractive sixth state, given the number of eligible individuals and the lack of integrated solutions for the frail, dual-eligible population. We're also in the final push of pre-launch activities for our Orlando Center. Like Tampa, it's comparably sized and represents our latest best practices in terms of building design, technology enablement, and operating model. We anticipate Orlando Center will be ready to accept new participants in the fourth quarter, barring any unforeseen. On December 1st, we completed the acquisition of two PACE centers in Southern California from Concerto Care. We consider this transaction more of a hybrid between an acquisition and a de novo, as it included a recently opened center in the Crenshaw neighborhood of Los Angeles with minimal census and a center in the final stages of the application for licensure in Bakersfield. We have been evaluating several alternatives to continue responsible growth in this market, and these centers facilitate a faster and more cost-effective expansion compared to building the centers from scratch, while enabling us to implement our operating model from day one. Of note, we anticipate these centers will add modest operating losses to our fully consolidated EBITDA near term as we work through the maturity curve. Taken together, we believe these new centers, along with our pending de novo center in Downey, demonstrate our ability to augment existing center growth with cost-effective expansions. We are excited for the opportunity to serve more seniors in more geographies over the next several months, while also increasing our overall portfolio capacity by approximately 30% once all of these centers are open, which we believe will be a meaningful driver of growth in the near-term and represent significant uplift in embedded earnings long-term. You'll recall that we measure and drive accountability for results through our five-pillar performance framework, which includes people, service, quality, growth, and financial KPIs. We measure these in every center, every month. We continue to see strong results across our people, service, and quality pillars, and will continue to invest in the people and resources necessary to further strengthen quality and compliance in each of our centers. Separately, we continue to see improvements in reducing external provider costs as our portfolio of clinical value initiatives mature. In the aggregate, we're trending ahead of internal targets on most initiatives fiscal year to date, with strong progress in areas such as inpatient admissions and Skilled Short Stay utilization. We've also observed meaningful improvement this quarter in areas such as reduced end-of-life costs and contract transportation costs. One new area of focus in the last quarter is ensuring we have the highest performing supportive housing network from a quality, compliance, and cost perspective. We're continually learning and improving as we go through compliance and quality audits. One of our key learnings is how dependent our quality, compliance, and financial performance is on the quality of nursing facilities and assisted living facilities in our network, given we have ultimate accountability for the care that is provided and administered in these settings. With this in mind, we have increased our focus on the quality and value of our supportive housing network. By ranking our providers on the dimensions of quality of care, compliance, cost, and cooperation, and by narrowing our network around higher performing facilities, we're able to ensure our participants have access to the highest performing providers in their community. We're seeing similar progress in the management of our general administrative expenses. This quarter, we saw a sequential decrease in G&A of approximately $3.6 million. Importantly, ongoing growth will help to rightsize our overall cost structure as we continue to expand revenue through existing center enrollment and new center development. Lastly, we're pleased to report that we're now operational across our entire portfolio with the first-ever PACE-specific instance of Epic. As we've discussed previously, this was a significant investment in dollars and time for the organization, and we view our new EMR as a chief enabler of increased operational productivity, efficiency, compliance, and clinical staff satisfaction going forward. While it will take some time to achieve full adoption and the expected benefits in our newer markets, we're already seeing early wins in terms of operational and clinical efficiencies. In summary, we believe we are improving the business every quarter, and I again want to thank my 2,100 InnovAge colleagues nationally who are working tirelessly to make this wonderful program a reality for participants every single day. We remain focused on the actions that are unlocking both near-term and long-term value, and believe it will translate into both enhanced competitive differentiation in the marketplace, as well as improved financial performance. Finally, I want to remind the audience that we're excited to be hosting our first Investor Day on February 27 in New York, where we will provide more details on the journey we are on. With that, I'll turn it over to Ben to walk through our quarterly financial performance. Thank you, Patrick. Today, I'll provide some highlights from our second quarter fiscal year 2024 financial performance, a reaffirmation of our fiscal 2024 guidance, and some insight into some of the trends we are seeing heading into the spring. While it is still early in our margin improvement initiatives, we continue to track to our internal targets and are pleased with the progress we have made so far this fiscal year. Starting with census, we ended the second quarter of fiscal year 2024 with 18 centers and approximately 6,780 participants as of December 31, 2023. We also reported 20,130 member months in the second quarter, a 3% increase to both ending census and member months compared to the first quarter. Total revenue increased by 3.5% to $188.9 million in the second quarter compared to the first quarter, due primarily to an increase in member months, coupled with an increase in capitation rates, primarily due to a one-time Medicare True-Up outside the regular payment cycle recorded in the second quarter. We incurred $101 million of external provider costs during the second quarter of fiscal 2024, a 1.6% increase compared to the first quarter. The sequential increase was driven by an increase in member months, partially offset by a decrease in cost per participant. The cost per participant decrease was driven by lower permanent nursing facility utilization, partially offset by an increase in inpatient utilization, which is not uncommon in the winter months. Cost of care, excluding depreciation and amortization of $54.3 million decreased 1.7% compared to the first quarter. The decrease was due to lower cost per participant, partially offset by the increase in member months. The cost per participant decrease was driven by a reduction in fleet expense, including contract transportation, fuel costs, and vehicle repairs and maintenance, as well as a reduction in supplies expense. This was partially offset by an increase in FTEs and annual wage rate increases. Center-L evel Contribution Margin, which we define as total revenue, less external provider costs and cost of care, excluding depreciation and amortization, was $33.6 million for the quarter, compared to $27.9 million in the first quarter. As a percentage of revenue, Center- Level Contribution Margin increased to 17.8%, compared to 15.3% in the first quarter, reflecting an improvement in the quality of our earnings in our centers. Sales and marketing expense was $5.9 million, an increase of approximately $500,000 compared to the prior quarter. The increase was primarily due to increased marketing spend as we launched our new marketing campaign in November and increased headcount. Corporate, general, and administrative expense declined to $25.2 million, a $3.7 million decrease compared to the first quarter. The decrease was primarily due to a reduction in third-party costs related to legal, consulting, and financial reporting, and decreased implementation costs associated with Epic. The decrease was partially offset by an increase in IT license fees, inclusive of Epic and bad debt. Net loss was $3.8 million, compared to net loss of $11 million in the first quarter. We recorded a net loss per share of $0.03 on both a basic and diluted basis, and our weighted average share count was approximately $135.9 million shares for the quarter on both a basic and fully diluted basis. Adjusted EBITDA, which we calculate by adding interest expense, taxes, depreciation and amortization, M&A, and de novo center development expenses, and other non-recurring or exceptional costs to net loss, was $7.8 million for the quarter, compared to $2.2 million in the first quarter. Our adjusted EBITDA margin was 4.1% for the second quarter, compared to 1.2% in the first quarter. De novo losses for the second quarter were $2.2 million and related to our acquisition of Concerto Care, which occurred on December 1st, and our centers in Florida. This compares to $1.6 million of de novo losses in the first quarter. Turning to our balance sheet, we ended the quarter with $54.1 million in cash and cash equivalents, plus $44.7 million in short-term investments. We had $83.7 million in total debt on the balance sheet, representing debt under our senior secured term loan, plus finance lease obligations and other commitments. For the second quarter, we recorded negative cash flow from operations of $9.3 million, and we had $1.6 million of capital expenditures, excluding the purchase price of Concerto Care. We are reaffirming our fiscal 2024 guidance, which now includes the ConcertoCare PACE acquisition. Based on the information as of today, we expect our ending census for fiscal year 2024 to be between 6,800 and 7,400 participants, and member months to be in the range of 79,000- 83,000. We are projecting total revenue in the range of $725 million-$775 million, and Adjusted EBITDA in the range of $12 million-$18 million. Finally, we anticipate that de novo losses for fiscal 2024 will be in the $10 million-$12 million range, which again, is inclusive of our recent acquisition of ConcertoCare PACE. In closing, I want to reiterate Patrick's comments, as we believe we are continuing to make improvements to the business every quarter. We remain focused on all aspects of the business to drive near-term and longer-term value, and we look forward to providing more details at our upcoming Investor Day on the 27th of February. We will provide details on the event later this week. Operator, that concludes our prepared remarks. Please open the call for questions. Thank you. And at this time, we will conduct a question-and-answer session. As a reminder, to ask a question, you need to press star one zero one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile a Q&A roster. One moment for our first question. Our first question will come from the line of Jason Cassorla from Citi. Your line is open. Great. Thanks for taking my questions. Ben, you noted a Medicare True-Up in the quarter. Apologies if I missed this, but can you help size that True-Up? And I guess in that context, you've previously discussed or suggested a strong kind of back half, EBITDA ramp as the fruits of your clinical value initiatives come to fruition. But, you know, in your prepared remarks, you talked about seasonality related to MA open enrollment period and other nuances. Maybe, in all that, can you just walk through how you're thinking about EBITDA progression for the rest of 2024 as well? Sure. And nice to hear your voice. So a couple of things that are embedded in that question. The first is that we are on track for our guidance that we issued earlier in the year, so we're reaffirming our guidance. I'd say over the course of the year, not unexpectedly, there are some puts and takes that get us there. So we had a final, final adjustment, which was a rate, a rate True-Up related to 2022. And it had to do with the fact that CMS gave us a little extra time in terms of submitting that, and it was a COVID-related factor. That came through in the second quarter, and that was a sort of meaningful increase to what we received in terms of Medicare rates in that quarter. We haven't disclosed or broken out the numbers specifically, in part because there are a number of factors that go into the course of the year. We just chose not to break out individual ones. But that gave us a good boost going into the back half of the year. Another factor that came into play here was a reduction in rates in California, which we're going to see in the back half of the year. That was an unexpected reduction versus a modest increase that we had in the forecast or in the budget going forward. And those two items, you know, to a large extent, sort of offset each other. And so that puts us on path towards getting to guidance for the back of the year. A couple other things I would say about enrollment. There is a seasonal component to enrollment, and Patrick, I know, will want to comment on that a little bit further, but that affects us as we go into the first quarter of the year. But by and large, all of these things together, as we look at the components together, end up with us reaffirming guidance and ending up with us being where we think we're going to come out. But, you know, as we indicated earlier in the year, we're quite confident on the destination towards which we're heading. But, you know, in any one particular quarter or, you know, we'll have slightly different factors that get us to that destination. Yeah. Hey, Jason, good to hear from you. Just two things maybe I may add to what Ben said is, you know, as it relates to risk adjustment accuracy, you probably recall us highlighting that as, you know, one of the core sort of pillars of building out our payer capabilities. And CMS had extended a deadline, for submission of 2022, calendar year 2022 risk scores. And so it gave us some extra time, and we were probably a little conservative on, given it was the first time we'd gone through it, really, as a team in an initiative like that, a bit conservative on our accrual. I think we're dialing that in and getting a better sense of that. We've got some third parties helping us to produce better estimates of, risk score accuracy changes. I think in the future, you know, I'm hoping that it's going to optimize our forecasting as well, and we'll be, you know, we'll just do a better job of understanding what period things are going to hit and how does it compare to our accrual. And then on Ben's point related to, you know, seasonality, you know, this was a fairly sort of loud and frenetic Medicare Advantage year. You know, there was, there was more, direct-to-consumer marketing than I think we've ever seen in, in our markets. And I think what Ben's hitting on is we'd really like to get a full, you know, fiscal year under our belt to see all the cycles, to see all the seasonality that's, that's, relevant to our business. And, you know, I think for those reasons, you know, some of what's coming from, you know, that kind of Annual Election Period doesn't hit us until Q3, and we're starting to, you know, try to understand what that means and does it have any impact on our growth, etc.. And then the CVI delays, I can, you know, I won't, I won't call out a specific, but for example, we had a nice opportunity that we saw where we were paying significantly above market rates for some ancillary services, and we were very successful in negotiating the contract. We probably under-clubbed the implementation complexity to get that rolled out on the timeline that we thought, and as a result, that CVI impact is delayed to later in the year. I think that's the kind of thing that Ben's hitting on by suggesting we're going to sort of stick with our guidance because there's a lot of puts and takes. Yeah, and I think of that one CVI point, it's important to recognize that we're gonna get the targeted amount of dollar savings that we always intended to get, but the contract really just started a couple of months later because it took a little longer to implement and negotiate. Got it. Okay, all very helpful. Appreciate it. Maybe, just a pointer on California, [rate]. I wanted to ask just broadly around the PMPM rate development backdrop, you know, how should we think about the moving pieces on the Medicaid side, right? Perhaps, you know, if you expect any other material changes to kind of mid-calendar year rate development, you know, how are rate discussions with state partners developing, you know, now that the Enhanced FMAP is winding down? And then, just on the MA Component, right, the proposed 2025 rate would suggest another sort of kind of tough year on that front. I guess I'm curious on how you're thinking about the MA side of the rate equation, for the second half of this fiscal year and, moving into 2025, will be helpful. Thanks. I'll start, Ben, maybe clean me up. You know, I think we're probably more focused on Medicaid rates, and it's still probably a bit too early to know what that's going to look like in the next fiscal year. I think what Ben pointed out is, in California, we came in below what we had targeted. You know, I would qualify that by saying that, you know, think of that as an industry impact in terms of PACE and not an InnovAge-specific impact. Lots of moving parts, but, you know, one notable part is, you know, notable driver would be the more, and with the passage of time, the further we get from COVID, the more reflective, you know, actual experience is predicting future experience from a claims perspective. There's still a lot of noise, if you will, in the, you know, in the rate-setting process that I think is a little bit of the lingering impacts of the data set related to COVID. So California's, I think, are only staying on the fiscal year, so, you know, it's having an unexpected impact in the back half of this fiscal year. Ben, anything to add? No, I think it's absolutely right. Okay, understood. Thanks. If I could squeeze in one last one, I just wanted to quickly follow up on cash flow. It looks like there's a $25 million headwind on deferred revenue year to date. Can you just help reconcile what that was related to, if there's any color there? Yeah, the deferred revenue really relates to Medicare, and it relates to how the first day of a month falls relative to a weekend. So what happens is, if you, if the first of the month falls on, like, a Sunday, if you will, well, Medicare payments and reimbursements are due on the first of the month. What happens is we receive it on the Friday beforehand, so essentially, in the prior month, if you will, by a couple of days. So when that occurs, we set up a deferred revenue account to adjust for that. When all of a sudden, the first of a month falls on a weekday, that gets cleaned up in the following quarter. So when you think about that deferred revenue payment, think about it as, does the first of the month fall on a weekend or not, and how does that impact the timing of the Medicare payment? Okay, fair enough. Thank you very much. Thank you. One moment for our next question. Our next question will come from the line of Jared Haase from William Blair. Your line is open. Yeah. Hey, guys. Good afternoon, and thanks for taking the questions. The first one from us, we're just hoping to dig into the de novo ramp a little bit. Congrats on getting the Tampa Facility open. Could you maybe just walk through or remind us a little bit on sort of what the expectations are in terms of how both census and profitability ramp for a de novo facility? And I think a related question here, obviously, with the Concerto acquisition in mind, you know, maybe you could talk a little bit about, you know, how that sort of profitability ramp kind of informs the equation in terms of your perception of sort of a build versus buy opportunity just in terms of future growth? Thanks. Yeah, sure. Why, why don't I, I'll start it off here, and then, Patrick will jump in with some comments here. First of all, thanks for the congrats. It was a great transaction for us. We're really excited about it. If you were to think about the Concerto acquisition, I guess really think of it as, you know, two facilities. You know, there's one, which is in Crenshaw, which is up and running, but has a very small census. So think of that as almost like a de-risked de novo, because our census is in the, you know, call it 20, 20 folks. And then think about the Bakersfield one, which is a center that's essentially fully constructed, basically awaiting approval to open, right? So when we look at that acquisition, we think of it as a basically de-risked de novo. But generally, the way we think about de novos is that, you know, it will take us on the order of six quarters, probably, to fill them up to the point where we get to a positive center-level contribution margin. And then it'll take us some time beyond that before they hit maturity. But really, it's in that first six quarters that we really watch the cash flow impact, especially carefully, because we obviously want to get them up to be contributors as quickly as possible. And so when we do our forecasting and we go through our strategic analysis about do we want to do de novos or do we want to do acquisitions, or in this case, kind of a hybrid de novo, that's the way we model out the business. Yeah, you know, I'll just add, you know, I mentioned the Investor Day on February 27th. You know, one of our goals at Investor Day is to bring more clarity to the de novo ramp-up and the sort of the unit economics of the business. So we'll do that. You know, in terms of what to expect with the de novo, you know, each market is different. You know, there's different density, there's different managed care landscape, different alternatives. But I would say that, you know, Sacramento's probably not a bad proxy for, you know, what we think we can accomplish in, say, you know, example or in Orlando. You know, it's a big market. There's a lot of opportunity, and we feel pretty good about our offering, and we've got, you know, a great team on the ground, and we, we've got a grand opening scheduled, I think, on March 3rd, 4th, excuse me. And so we've got a great opportunity just to introduce that product to the community, and, and we're feeling really good about it. And we're also feeling good about Sacramento growth. Just as, you know, while it's not a new market, you know, in terms of a timeline, it was, it was, as you know, sanctioned not long after it was operational. So in many ways, Sacramento is a new market, as we think about the ramp and, you know, we're really pleased with how the team is doing there. Okay, that's super helpful. Thank you for that. And then I wanted to follow up, and I think the theme of some administrative delays, kind of at the state level, that's maybe creating a little bit of a headwind for enrollment trends. I think that's come up in recent quarters. I was curious, is there anything that you guys are able to do internally in terms of once you've identified an eligible potential participant, sort of working with them, working with their families, maybe helping them get through that process and maybe speed up some of that time? Is that something that you have any control over, or is it largely out of your hands? Well, it is a great question. You know, I tend to ask the team, you know, the same question as well. You know, when there are delays that are sort of outside of our locus of control, are there things we can do to, you know, still help the family see the end of the, you know, see the end of the process and feel confident that this is gonna be the right solution, and it's kind of worth the wait. So we certainly do engage with individuals and their family and make them aware of administrative processing delays and set their expectations of when we think enrollment will occur. And, you know, more times than not, we're certainly able to achieve that and, you know, keep that individual in the funnel and get them access to the services that they need. At the same time, we're dealing with a very vulnerable population, and most of the individuals that are looking to access PACE are in need of rather immediate services. And so delays with the processing of applications at the state can and do result in people making alternative choices. Sometimes it's going back into the state Fee-for-Service program. Sometimes it could be, you know, if it's in California, it could be with a PACE competitor in the same territory, or they could pursue maybe Medicare Advantage in the belief that there's an option there. But it is definitely something we do our best to manage. We're working very closely with our state's audit. The states have been great partners. It's just a reality that they often use subcontractors for this work, and, you know, that adds a layer of complexity for us to manage. Okay, that makes sense, and appreciate the context there. And maybe I'll just sneak in one more question. It sounded like you launched a new marketing campaign during the quarter. Would love to just hear, you know, any specifics in terms of anything that's maybe unique or has changed from prior years in terms of just how you're sort of communicating the message about innovative services. Yeah, another great question. We'll be sharing some of our latest creative, if you will, at our Investor Day, and so people get a better sense for it if they haven't seen, you know, at least our broadcast TV work. You know, I think one of the things that we're trying to do is to dispel that, you know, PACE is only for the absolute most vulnerable. You know, there are a lot of individuals that qualify for PACE that see PACE as a place to enjoy socialization, you know, meet new friends, address nutritional deficits, and that's a large, you know, a large senior population. And so I think we've tried to use our creative to drive a message home that PACE is a real resource to a broad segment of the frail senior community. I think maybe a second thing that's new is we're trying to appeal more directly to family members. You know, I think in many cases, family members find PACE as much a solution for them as they do for their loved one, and I think our messaging is starting to appeal, you know, to the eldest daughter. You know, our data will tell us that that's a big decision maker, as an example. And so I think we're just trying to appeal to a broader market segment, and I think we've been successful at that. We've got a lot of great feedback on the creative. Perfect. Makes a lot of sense. I'll go ahead and leave it there and hop back in the queue. Thank you. Thank you. And as a reminder, that's star one for questions, star one. One moment for our next question. Our next question comes from the line of Jamie Perse from Goldman Sachs. Your line is open. Hey, thanks. Good afternoon. Maybe just starting with the Colorado enrollment trends, can you provide a little more detail on just the census rebuild there and patient mix that you're getting? I think you mentioned, you know, some balance between community versus facility patients, broadly, but any surprises there just in terms of the patient mix, and the broader trends on Colorado census rebuild? You know, Jamie, I think I would say that everything's going as we expected and hoped in Colorado. I think we're on the other side of what might have been some pent-up demand. And, you know, and I would say that that pent-up demand was maybe less reflective of a traditional participant mix. I think we're on the other side of that. At the same time, I think that, you know, at least our gross enrollments are back to sort of the best period in the company's history. So, you know, coming out of sanctions, you know, we set a goal for ourselves, at least near term, to let's get the company back on kind of the track it was in sort of the, you know, doing all the right things, and I think we're seeing that. At the same time, you know, it's an example of a market where, you know, the demand is probably a bit larger than what's getting processed through the funnel. And we are working closely, you know, on that issue, but still, you know, it's leading to responsible growth in Colorado, and we're feeling really good about it. Okay, thanks for that. And then just on the seasonality comments, you talked about inpatient in the quarter. Any way to put numbers to that, just in terms of, you know, how that impacted external provider costs in the quarter? And then as we think about your third fiscal quarter, how should we, you know, be modeling that rolling off? What's typical from a seasonality perspective as some of those inpatient costs come down? You know, first, I would say the seasonality, the relevance of a seasonality consideration, you know, is probably more appropriate through the lens of the third quarter versus the second quarter, because people are, you know, people are going through the annual election period, and, you know, it's really going to hit us if people decided to leave PACE for Medicare Advantage. You know, we're just now kind of seeing that in the numbers. I don't think we actually have a good read yet on, you know, what's the right seasonality, you know, sort of cycle for the business. You know, one day we'll see information that, you know, I think gives us confidence that the seasonality could be muted, and the next day we see some something to the contrary. So I think we're still trying to figure out exactly what's the right guidance around seasonality. You know, it's just gonna take some experience, real time to offer that. Ben, anything you would add in terms of, you know? No, I think the second part of your question, I think, was really geared towards how do I think about census and member months for the back half of the year. And I guess I would tell you that, you know, we're not really providing any guidance on a quarter-by-quarter basis. You've got the data now on enrollment and member months for Q1 and Q2. You know, if there's any seasonality in enrollment, it's really probably related to the third quarter, which tends to be a little bit lower for the reasons that Patrick just articulated. But then if you think about where we are in terms of our guidance targets being unchanged from where we were originally, I think you can take those three pieces of information and put them together and come up with a reasonable expectation for how we might perform over the back half of the year. Okay. And then, last quick one for me, just on maybe longer term gross margin, progression. You, you've talked in the past about rebuilding that, you know, maybe with, with different building blocks between the, the COG lines. How are you feeling broadly about that margin recovery? You know, any areas you'd flag as being, you know, ahead or behind of your expectations, and level of confidence in rebuilding that over the next, 12-18 months? Yeah, great question. I'll start and let Ben weigh in. You know, I would, when I think about margin, I think we're beginning to think about it across two dimensions in the business. I think the first priority is to get our overall center level contribution margin above 20%, and we wanna do that across the portfolio. And that's inclusive of the investments we've made to fortify quality and compliance and technology over the last, you know, over the last year. And then I think, you know, sort of the next consideration is more around this Adjusted EBITDA target. And, you know, we believe we can, you know, substantially achieve a high single digit, low double digit Adjusted EBITDA. But as we've talked about before, it could have a little different composition, you know, on how it's achieved, because we're running a little heavier on the, you know, salaries, wages, and benefits in the market, not only because of we've hired in more staff and fortified our operating model, but, you know, there's national, excuse me, natural inflationary factors that are, you know, a part of that as well, that we and other healthcare organizations are dealing with. And, you know, the long-term margin targets, I think we think of those inclusive of additional scale over time, because as we grow, we're gonna continue to leverage our corporate G&A, our Epic investment, etc.. So at this stage, I think we're feeling confident, but we're very focused on the CLCM as sort of that leading indicator of what's achievable further down on the P&L. Ben, anything to add? No, I think you captured it perfectly. Appreciate it. Thank you. Thank you. I'm not showing any further questions at this time. I would now like to turn it back to Patrick Blair for any closing remarks. Well, appreciate those of you who took the time to dial in and hear more about our progress. I think I'll close with how I opened. We're improving the business every quarter. You know, delivering on that commitment is extremely important to myself and to the team. You know, I think the second is just transparency. You know, we're trying to provide as much information as possible to help you really understand how the business is operating, and you can count on us to be as transparent as possible with everything that we face as we transform the company. Then I just would like to encourage everyone to join us, whether that's in person or through a recorded call, Investor Day on February 27th. The goal there is to sort of reintroduce you to the company with a bit more detail than we're able to provide here on these calls and answer your questions and, you know, give you just a deeper look at the business and introduce you to what I think is a fantastic leadership team that can, you know, run a much larger company. We're excited to share the story with you. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.